Verrica (VRCA) CEO Jayson Rieger Buys 25,000 Shares

What Happened

• Jayson Rieger, CEO, President and a director of Verrica Pharmaceuticals (VRCA), made open-market purchases totaling 25,000 shares in mid‑August 2026. He acquired 20,000 shares on 2026-08-14 for a reported weighted average price of $5.06 (total ≈ $101,200) and 5,000 shares on 2026-08-17 at $4.91 (total $24,550). Combined cost of the purchases was about $125,750.
• These were purchases (code P on the Form 4), which are buying transactions rather than sales; the filing does not state Rieger’s motivations.

Key Details

• Transaction dates and prices:
  • 2026-08-14: 20,000 shares at a weighted average of $5.06 (reported range $5.04–$5.088). (Footnote F1: weighted-average price; breakdown available on request.)
  • 2026-08-17: 5,000 shares at $4.91 (total $24,550).
• Total shares purchased: 25,000; total cash outlay ≈ $125,750.
• Shares owned after the transactions: Not specified in the provided filing.
• Footnote F2: Some of the shares are held in separate trusts for immediate family members for which Rieger is a co‑trustee; he disclaims beneficial ownership of those trust shares in this filing.
• Filing timeliness: Form 4 was filed on 2026-08-18 covering transactions on 8/14 and 8/17; the filing appears to be timely (within the SEC’s two business-day requirement).

Context

• Purchases by executives are often watched by investors as a direct insider buy signal, but filings are factual records and do not explain intent.
• No options exercises, gifts, or sales were reported in this filing — only open-market purchases (P).